Increasing Drug Importation To Lower Prices for American Patients

The order directs the Secretary of Health and Human Services to take three specific actions to expand drug importation: grant waivers to individuals allowing importation of prescription drugs when it poses no additional public safety risk and lowers costs; authorize re-importation of insulin products upon a finding that it is required for emergency medical care; and complete the pending rulemaking process to implement the proposed rule allowing importation of certain prescription drugs from Canada under the Federal Food, Drug, and Cosmetic Act.

The order does not itself change any law or immediately permit importation — each action is conditioned on findings, waivers, or completed rulemaking by HHS. It also includes standard general provisions clarifying that nothing in the order impairs existing agency authority, creates enforceable individual rights, or obligates spending beyond available appropriations.

American patients who purchase prescription drugs, particularly insulin-dependent patients who may benefit from re-importation authorization, and importers or individuals seeking waivers. Pharmacies and drug manufacturers operating in Canada and other lower-cost markets may also be affected by expanded importation pathways.

If HHS completes the required rulemaking and grants waivers, American consumers — especially those buying insulin — could gain access to the same brand-name drugs at lower prices. Actual savings depend on future agency action rather than anything the order itself immediately changes.

The order works in three parallel tracks: individual importation waivers granted case-by-case by HHS when safety and cost conditions are met; a specific insulin re-importation finding the Secretary must make under an existing FDCA emergency medical care provision; and completion of a rulemaking process that was already proposed but not finalized for broader Canadian importation. No single action takes immediate legal effect — each requires HHS to exercise discretion, complete administrative procedures, or make statutory findings first. No reporting deadlines or OMB oversight mechanisms are specified.